1. Home
  2. INKT
  3. INKT News

Latest MiNK Therapeutics Inc. (INKT) News on November 19, 2025

INKT

GuruFocus.com

4 days ago

MiNK Therapeutics Inc (INKT) Q3 2025 Earnings Call Highlights: Promising Clinical Results and ...

MiNK Therapeutics (INKT) Earnings Call Transcript
INKT

Motley Fool

5 days ago

MiNK Therapeutics (INKT) Earnings Call Transcript

MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation
INKT

GlobeNewswire

5 days ago

MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation

MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025
INKT

GlobeNewswire

12 days ago

MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

INKT

Business Wire

14 days ago

Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report

MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development
INKT

GlobeNewswire

14 days ago

MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development

MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting
INKT

GlobeNewswire

20 days ago

MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
INKT

GlobeNewswire

5 months ago

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients
INKT

GlobeNewswire

6 months ago

MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients

INKT

GuruFocus.com

6 months ago

MiNK Therapeutics Inc (INKT) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ...

INKT

Thomson Reuters StreetEvents

6 months ago

Q1 2025 Mink Therapeutics Inc Earnings Call

MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress
INKT

GlobeNewswire

6 months ago

MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report
INKT

GlobeNewswire

6 months ago

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

INKT

GuruFocus.com

8 months ago

MiNK Therapeutics Inc (INKT) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...

INKT

Thomson Reuters StreetEvents

8 months ago

Q4 2024 Mink Therapeutics Inc Earnings Call

MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress
INKT

GlobeNewswire

8 months ago

MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress

Are MiNK Therapeutics, Inc. (NASDAQ:INKT) Investors Paying Above The Intrinsic Value?
INKT

Simply Wall St.

8 months ago

Are MiNK Therapeutics, Inc. (NASDAQ:INKT) Investors Paying Above The Intrinsic Value?

MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report
INKT

GlobeNewswire

9 months ago

MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting
INKT

GlobeNewswire

9 months ago

MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting

MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements
INKT

GlobeNewswire

9 months ago

MiNK Therapeutics Regains Full Compliance with Nasdaq Listing Requirements

MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting
INKT

GlobeNewswire

9 months ago

MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting

MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI
INKT

GlobeNewswire

10 months ago

MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI

MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting
INKT

GlobeNewswire

a year ago

MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting

INKT

Thomson Reuters StreetEvents

a year ago

Q3 2024 Mink Therapeutics Inc Earnings Call

INKT

GuruFocus.com

a year ago

MiNK Therapeutics Inc (INKT) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...

MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update
INKT

GlobeNewswire

a year ago

MiNK Therapeutics Reports Third Quarter 2024 Results and Business Update

MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report
INKT

GlobeNewswire

a year ago

MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report

MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024
INKT

GlobeNewswire

a year ago

MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024

MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors
INKT

GlobeNewswire

a year ago

MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors

INKT

GuruFocus.com

a year ago

MiNK Therapeutics Inc (INKT) Q2 2024 Earnings Call Highlights: Strategic Advances Amid ...

MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors
INKT

GlobeNewswire

a year ago

MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors

MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024
INKT

GlobeNewswire

a year ago

MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024

MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference
INKT

GlobeNewswire

a year ago

MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference

MiNK Reports Second Quarter 2024 Results and Business Update
INKT

GlobeNewswire

a year ago

MiNK Reports Second Quarter 2024 Results and Business Update

MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report
INKT

GlobeNewswire

a year ago

MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report

MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement
INKT

GlobeNewswire

a year ago

MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement

MiNK Therapeutics, Inc. (INKT) Upgraded to Strong Buy: Here's What You Should Know
INKT

Zacks

a year ago

MiNK Therapeutics, Inc. (INKT) Upgraded to Strong Buy: Here's What You Should Know

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
INKT

GlobeNewswire

a year ago

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting
INKT

GlobeNewswire

a year ago

MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

INKT

GuruFocus.com

2 years ago

MiNK Therapeutics Inc (INKT) Q1 2024 Earnings Call Transcript Highlights: Strategic Reductions ...

MiNK Reports First Quarter 2024 Results
INKT

GlobeNewswire

2 years ago

MiNK Reports First Quarter 2024 Results

MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer
INKT

GlobeNewswire

2 years ago

MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer

MiNK to Provide Corporate Update and First Quarter 2024 Financial Report
INKT

GlobeNewswire

2 years ago

MiNK to Provide Corporate Update and First Quarter 2024 Financial Report

This MiNK Therapeutics Insider Increased Their Holding In The Last Year
INKT

Simply Wall St.

2 years ago

This MiNK Therapeutics Insider Increased Their Holding In The Last Year

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
INKT

GlobeNewswire

2 years ago

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

All You Need to Know About MiNK Therapeutics, Inc. (INKT) Rating Upgrade to Buy
INKT

Zacks

2 years ago

All You Need to Know About MiNK Therapeutics, Inc. (INKT) Rating Upgrade to Buy

MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call Transcript
INKT

Insider Monkey

2 years ago

MiNK Therapeutics, Inc. (NASDAQ:INKT) Q4 2023 Earnings Call Transcript

INKT

Thomson Reuters StreetEvents

2 years ago

Q4 2023 Mink Therapeutics Inc Earnings Call

MiNK Reports Fourth Quarter and Year-End 2023 Results
INKT

GlobeNewswire

2 years ago

MiNK Reports Fourth Quarter and Year-End 2023 Results

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
INKT

GlobeNewswire

2 years ago

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
INKT

GlobeNewswire

2 years ago

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
INKT

GlobeNewswire

2 years ago

First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab

MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications
INKT

GlobeNewswire

2 years ago

MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications

INKT

ACCESSWIRE

2 years ago

Nocturne Acquisition Corporation Announces Postponement of Extraordinary General Meeting

MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
INKT

GlobeNewswire

2 years ago

MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

Invesco Closed-End Funds Declare Dividends
INKT

PR Newswire

2 years ago

Invesco Closed-End Funds Declare Dividends

BCB Bancorp, Inc. (NASDAQ:BCBP) most popular amongst retail investors who own 51% of the shares, institutions hold 36%
INKT

Simply Wall St.

2 years ago

BCB Bancorp, Inc. (NASDAQ:BCBP) most popular amongst retail investors who own 51% of the shares, institutions hold 36%

Broadwind (NASDAQ:BWEN) Shareholders Will Want The ROCE Trajectory To Continue
INKT

Simply Wall St.

2 years ago

Broadwind (NASDAQ:BWEN) Shareholders Will Want The ROCE Trajectory To Continue

Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
INKT

GlobeNewswire

2 years ago

Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update
INKT

Zacks

2 years ago

Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update

Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida
INKT

GlobeNewswire

2 years ago

Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida

We're Keeping An Eye On International Tower Hill Mines' (TSE:ITH) Cash Burn Rate
INKT

Simply Wall St.

2 years ago

We're Keeping An Eye On International Tower Hill Mines' (TSE:ITH) Cash Burn Rate

A2Z Smart Technologies Closes Previously Announced US$4.7 Million Registered Direct Offerings, Inclusive of $1.5 Million Raised in December 2023
INKT

ACCESSWIRE

2 years ago

A2Z Smart Technologies Closes Previously Announced US$4.7 Million Registered Direct Offerings, Inclusive of $1.5 Million Raised in December 2023

4 Electronics Semiconductor Stocks to Escape Macro Headwinds
INKT

Zacks

2 years ago

4 Electronics Semiconductor Stocks to Escape Macro Headwinds

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INKT

PR Newswire

2 years ago

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development
INKT

GlobeNewswire

2 years ago

ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development

Compugen (NASDAQ:CGEN) delivers shareholders impressive 144% return over 1 year, surging 158% in the last week alone
INKT

Simply Wall St.

2 years ago

Compugen (NASDAQ:CGEN) delivers shareholders impressive 144% return over 1 year, surging 158% in the last week alone

With 61% ownership of the shares, Lincoln Educational Services Corporation (NASDAQ:LINC) is heavily dominated by institutional owners
INKT

Simply Wall St.

2 years ago

With 61% ownership of the shares, Lincoln Educational Services Corporation (NASDAQ:LINC) is heavily dominated by institutional owners

Life Science Investor Forum: Presentations Now Available for Online Viewing
INKT

GlobeNewswire

2 years ago

Life Science Investor Forum: Presentations Now Available for Online Viewing

7 Promising Penny Stocks With the Potential to Defy Expectations
INKT

InvestorPlace

2 years ago

7 Promising Penny Stocks With the Potential to Defy Expectations

What Makes Corvus (CRVS) a New Buy Stock
INKT

Zacks

2 years ago

What Makes Corvus (CRVS) a New Buy Stock

Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation
INKT

Simply Wall St.

2 years ago

Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn Situation

GreenPower Panel Shares Real-World Experiences from Deploying the Type A Nano BEAST in Special Needs Situations
INKT

CNW Group

2 years ago

GreenPower Panel Shares Real-World Experiences from Deploying the Type A Nano BEAST in Special Needs Situations

Purple Announces Positive Black Friday/Cyber Monday Weekend Selling Period and Reiterates 2023 Full Year Outlook Ahead of Investor Conferences
INKT

PR Newswire

2 years ago

Purple Announces Positive Black Friday/Cyber Monday Weekend Selling Period and Reiterates 2023 Full Year Outlook Ahead of Investor Conferences

Is It Too Late To Consider Buying Live Ventures Incorporated (NASDAQ:LIVE)?
INKT

Simply Wall St.

2 years ago

Is It Too Late To Consider Buying Live Ventures Incorporated (NASDAQ:LIVE)?

GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy
INKT

GlobeNewswire

2 years ago

GeneDx Presents New Data at the American Epilepsy Society Annual Meeting Demonstrating That Exome Sequencing Outperforms Multi-Gene Panels for Patients with Epilepsy

Positive Signs As Multiple Insiders Buy Investar Holding Stock
INKT

Simply Wall St.

2 years ago

Positive Signs As Multiple Insiders Buy Investar Holding Stock

TeraWulf Inc. (NASDAQ:WULF) Analysts Just Slashed Next Year's Estimates
INKT

Simply Wall St.

2 years ago

TeraWulf Inc. (NASDAQ:WULF) Analysts Just Slashed Next Year's Estimates

Inogen Announces Leadership Change with the Appointment of Kevin Smith as President and CEO
INKT

Business Wire

2 years ago

Inogen Announces Leadership Change with the Appointment of Kevin Smith as President and CEO

FitLife Brands Announces Third Quarter 2023 Results
INKT

GlobeNewswire

2 years ago

FitLife Brands Announces Third Quarter 2023 Results

Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023
INKT

GlobeNewswire

2 years ago

Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023

Aqua Metals, Inc. (NASDAQ:AQMS) Q3 2023 Earnings Call Transcript
INKT

Insider Monkey

2 years ago

Aqua Metals, Inc. (NASDAQ:AQMS) Q3 2023 Earnings Call Transcript

INKT

GuruFocus.com

2 years ago

MiNK Therapeutics Inc (INKT) Reports Q3 2023 Results: Clinical Progress Amid Financial Challenges

MiNK Therapeutics Reports Third Quarter 2023 Results
INKT

GlobeNewswire

2 years ago

MiNK Therapeutics Reports Third Quarter 2023 Results

Full House Resorts Announces Strong Third Quarter Results
INKT

GlobeNewswire

2 years ago

Full House Resorts Announces Strong Third Quarter Results

SHL Telemedicine Establishes US Nationwide Cardiology Network for ECG Interpretations and Telehealth Visits
INKT

Business Wire

2 years ago

SHL Telemedicine Establishes US Nationwide Cardiology Network for ECG Interpretations and Telehealth Visits

Meridian (NASDAQ:MRBK) Could Be A Buy For Its Upcoming Dividend
INKT

Simply Wall St.

2 years ago

Meridian (NASDAQ:MRBK) Could Be A Buy For Its Upcoming Dividend

Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)
INKT

PR Newswire

2 years ago

Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)

Share on Social Networks: